Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Trial details
- Registry ID
- NCT07901738
- Drugs studied
- Zopapogene imadenovec-drba
TrialRedline tracks 2 clinical trials sponsored by Precigen, Inc: 1 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in ChildrenNCT07901738 | Zopapogene imadenovec-drba | Not yet recruiting | 2029-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151 | PRGN-2009 plus Pembrolizumab | Recruiting | 2026-11-11Estimated |
Names as written in the registry records.
NCT06157151 · Precigen, Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.. After: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer..
Before: 46 participants (planned). After: 24 participants (planned).
Before: 30 Jan 2028. After: 11 Nov 2026.